低预后女性的累积活产率
该研究分析荷兰多中心观察性队列中551例低预后女性,按POSEIDON标准分组,评估18个月内多个IVF/ICSI周期的累积活产率。低预后女性总体累积活产率约56%,各组间存在差异,主要归因于女性年龄的影响。
要点
- 低预后女性18个月内累积活产率平均约56%。
- 年轻意外poor和suboptimal应答者累积活产率分别约65%和68%。
- 年轻预期poor应答者累积活产率约59%。
核心结论
- 低预后女性的累积活产率在POSEIDON各组间存在差异,这种异质性主要由女性年龄决定,反映了卵母细胞质量的重要性。
- 年轻女性尽管定量参数降低,当前IVF/ICSI治疗在多个完整周期后仍达到相对较高的累积活产率。
- 年长女性由于定量和定性参数同时下降,多个完整周期后累积活产率仍相对较低。
- 由于没有有效干预措施来对抗这种下降,临床管理目前依赖于适当的咨询。
研究设计与样本
- 本研究分析了一项荷兰多中心观察性队列研究的数据,纳入551例低预后女性,年龄<44岁,于2011年至2014年间开始IVF/ICSI治疗,第一治疗周期接受固定FSH剂量150 IU/天。
- 低预后女性根据年龄(大于或小于35岁)、抗苗勒管激素(AMH)水平(高于或低于0.96 ng/ml)以及第一周期标准刺激中的卵巢反应(poor或suboptimal)被分类至POSEIDON组之一。
- 主要结局是18个月治疗内多个完整IVF/ICSI周期的累积活产率,包括所有后续新鲜和冻融胚胎移植。
- 累积发生率曲线采用乐观和保守两种分析方法获得。
主要发现
- 低预后女性18个月IVF/ICSI治疗后的累积活产率平均约56%。
- 年轻意外poor应答者(n=38)累积活产率约65%,年轻suboptimal应答者(n=179)约68%,年轻预期poor应答者(n=65)约59%。
- 年长意外poor应答者(n=41)累积活产率约42%,年长suboptimal应答者(n=102)约54%,年长预期poor应答者(n=126)约39%。
- 作为对照,卵巢储备正常的年轻正常应答者(n=164)累积活产率约72%,年长正常应答者(n=78)约58%(18个月治疗内)。
- POSEIDON各组间新鲜治疗周期数未见大的差异,18个月随访内平均每名女性两个新鲜周期。
临床怎么用
- 作者认为,由于没有有效干预措施来对抗卵巢储备下降,临床管理目前依赖于适当的咨询。
局限性
- 某些(亚)组样本量小,降低了估计的精确度。
- 周期之间允许小幅调整FSH剂量,导致治疗差异。
- 然而,这与当前日常实践一致,并增加了研究结果的普遍性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Do cumulative live birth rates (CLBRs) over multiple IVF/ICSI cycles confirm the low prognosis in women stratified according to the POSEIDON criteria? SUMMARY ANSWER: The CLBR of low-prognosis women is ~56% over 18 months of IVF/ICSI treatment and varies between the POSEIDON groups, which is primarily attributable to the impact of female age. WHAT IS KNOWN ALREADY: The POSEIDON group recently proposed a new stratification for low-prognosis women in IVF/ICSI treatment, with the aim to define more homogenous populations for clinical trials and stimulate a patient-tailored therapeutic approach. These new criteria combine qualitative and quantitative parameters to create four groups of low-prognosis women with supposedly similar biologic characteristics. STUDY DESIGN, SIZE, DURATION: This study analyzed the data of a Dutch multicenter observational cohort study including 551 low-prognosis women, aged <44 years, who initiated IVF/ICSI treatment between 2011 and 2014 and were treated with a fixed FSH dose of 150 IU/day in the first treatment cycle. PARTICIPANTS/MATERIALS, SETTING, METHODS: Low-prognosis women were categorized into one of the POSEIDON groups based on their age (younger or older than 35 years), anti-Müllerian hormone (AMH) level (above or below 0.96 ng/ml), and the ovarian response (poor or suboptimal) in their first cycle of standard stimulation. The primary outcome was the CLBR over multiple complete IVF/ICSI cycles, including all subsequent fresh and frozen-thawed embryo transfers, within 18 months of treatment. Cumulative incidence curves were obtained using an optimistic and a conservative analytic approach. MAIN RESULTS AND THE ROLE OF CHANCE: The CLBR of the low-prognosis women was on average ~56% over 18 months of IVF/ICSI treatment. Younger unexpected poor (n = 38) and suboptimal (n = 179) responders had a CLBR of ~65% and ~68%, respectively, and younger expected poor responders (n = 65) had a CLBR of ~59%. The CLBR of older unexpected poor (n = 41) and suboptimal responders (n = 102) was ~42% and ~54%, respectively, and of older expected poor responders (n = 126) ~39%. For comparison, the CLBR of younger (n = 164) and older (n = 78) normal responders with an adequate ovarian reserve was ~72% and ~58% over 18 months of treatment, respectively. No large differences were observed in the number of fresh treatment cycles between the POSEIDON groups, with an average of two fresh cycles per woman within 18 months of follow-up. LIMITATIONS, REASONS FOR CAUTION: Small numbers in some (sub)groups reduced the precision of the estimates. However, our findings provide the first relevant indication of the CLBR of low-prognosis women in the POSEIDON groups. Small FSH dose adjustments between cycles were allowed, inducing therapeutic disparity. Yet, this is in accordance with current daily practice and increases the generalizability of our findings. WIDER IMPLICATIONS OF THE FINDINGS: The CLBRs vary between the POSEIDON groups. This heterogeneity is primarily determined by a woman's age, reflecting the importance of oocyte quality. In younger women, current IVF/ICSI treatment reaches relatively high CLBR over multiple complete cycles, despite reduced quantitative parameters. In older women, the CLBR remains relatively low over multiple complete cycles, due to the co-occurring decline in quantitative and qualitative parameters. As no effective interventions exist to counteract this decline, clinical management currently relies on proper counselling. STUDY FUNDING/COMPETING INTEREST(S): No external funds were obtained for this study. J.A.L. is supported by a Research Fellowship grant and received an unrestricted personal grant from Merck BV. S.C.O., T.C.v.T., and H.L.T. received an unrestricted personal grant from Merck BV. C.B.L. received research grants from Merck, Ferring, and Guerbet. K.F. received unrestricted research grants from Merck Serono, Ferring, and GoodLife. She also received fees for lectures and consultancy from Ferring and GoodLife. A.H. declares that the Department of Obstetrics and Gynaecology, University Medical Centre Groningen received an unrestricted research grant from Ferring Pharmaceuticals BV, the Netherlands. J.S.E.L. has received unrestricted research grants from Ferring, Zon-MW, and The Dutch Heart Association. He also received travel grants and consultancy fees from Danone, Euroscreen, Ferring, AnshLabs, and Titus Healthcare. B.W.J.M. is supported by an National Health and Medical Research Council Practitioner Fellowship (GNT1082548) and reports consultancy work for ObsEva, Merck, and Guerbet. He also received a research grant from Merck BV and travel support from Guerbet. F.J.M.B. received monetary compensation as a member of the external advisory board for Merck Serono (the Netherlands) and Ferring Pharmaceuticals BV (the Netherlands) for advisory work for Gedeon Richter (Belgium) and Roche Diagnostics on automated AMH assay development, and for a research cooperation with Ansh Labs (USA). All other authors have nothing to declare. TRIAL REGISTRATION NUMBER: Not applicable.
引用
- Leijdekkers JA, Eijkemans MJC, van Tilborg TC, et al. Cumulative live birth rates in low-prognosis women. Hum Reprod. 2019. PMID: 31125412. doi:10.1093/humrep/dez051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。